BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21340788)

  • 1. Multiplex PCR (MPCR) Screening Can Detect Small Intragenic p53 Deletion and Insertion Mutations.
    Runnebaum IB; Wang-Gohrke S
    Methods Mol Med; 2001; 39():329-35. PubMed ID: 21340788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers.
    Jego N; Thomas G; Hamelin R
    Oncogene; 1993 Jan; 8(1):209-13. PubMed ID: 8380918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines.
    Runnebaum IB; Tong XW; Moebus V; Heilmann V; Kieback DG; Kreienberg R
    Hum Genet; 1994 Jun; 93(6):620-4. PubMed ID: 8005584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
    Buller RE; Shahin MS; Holmes RW; Hatterman M; Kirby PA; Sood AK
    Am J Obstet Gynecol; 2001 Apr; 184(5):891-902; discussion 902-3. PubMed ID: 11303196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers.
    Simms LA; Radford-Smith G; Biden KG; Buttenshaw R; Cummings M; Jass JR; Young J; Meltzer SJ; Leggett BA
    Oncogene; 1998 Oct; 17(15):2003-8. PubMed ID: 9788444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
    Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion and insertion in vivo somatic mutations in the hypoxanthine phosphoribosyltransferase (hprt) gene of human T-lymphocytes.
    Burkhart-Schultz KJ; Jones IM
    Environ Mol Mutagen; 1997; 30(4):371-84. PubMed ID: 9435878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
    Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
    Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model.
    Greenblatt MS; Grollman AP; Harris CC
    Cancer Res; 1996 May; 56(9):2130-6. PubMed ID: 8616861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon 5 of the p53 gene is a target for deletions in ovarian cancer.
    Angelopoulou K; Levesque MA; Katsaros D; Shipman R; Diamandis EP
    Clin Chem; 1998 Jan; 44(1):72-7. PubMed ID: 9550561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different mutation profiles associated to P53 accumulation in colorectal cancer.
    López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
    Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
    Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene.
    Yamada K; Zhong X; Kanazawa S; Koike J; Tsujita K; Hemmi H
    Oncol Rep; 2003; 10(4):859-66. PubMed ID: 12792735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
    Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
    Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutation is a common genetic event in ovarian carcinoma.
    Milner BJ; Allan LA; Eccles DM; Kitchener HC; Leonard RC; Kelly KF; Parkin DE; Haites NE
    Cancer Res; 1993 May; 53(9):2128-32. PubMed ID: 8481915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.